CABOMETYX® is indicated for the treatment of advanced renal cell carcinoma (RCC):1
– in treatment-naïve adults with intermediate or poor risk
– in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

CABOMETYX® is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.1

1. CABOMETYX® SmPC